The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu ...

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter.

The COVID-19 pandemic may have ended a long time ago, but the European Commission is still ordering 146 million doses of coronavirus vaccines, Berliner Zeitung reports. The costs, however, remain ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S.

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

President Trump’s chief cost-cutter cheered an effort to persuade federal workers to quit — in a fashion that closely ...

Chief Executive Officer Albert Bourla said at the JPMorgan Healthcare Conference on Monday. Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company ...

(NYSE:PFE) has temporarily avoided a standoff with activist investor Starboard Value LP. According to Bloomberg sources, ...